TG Therapeutics, Inc.
General ticker "TGTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $4.8B (TTM average)
TG Therapeutics, Inc. follows the US Stock Market performance with the rate: 47.6%.
Estimated limits based on current volatility of 3.1%: low 53.32$, high 56.72$
Factors to consider:
- Total employees count: 338 as of 2024
- US accounted for 94.2% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Regulatory and compliance, Clinical trial disruptions, Labor/talent shortage/retention, Market competition, Litigation risks
- Current price 56.9% above estimated high
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [18.64$, 36.26$]
- 2026-12-31 to 2027-12-31 estimated range: [17.23$, 33.57$]
Financial Metrics affecting the TGTX estimates:
- Positive: with PPE of 11.0 at the end of fiscal year the price was neutral
- Negative: Operating cash flow per share per price, % of -0.56 <= 0.28
- Positive: Operating profit margin, % of 20.01 > 18.77
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of -8.66 <= -0.75
- Positive: Return on assets ratio (scaled to [-100,100]) of 29.61 > 6.06
- Positive: Investing cash flow per share per price, % of 0.31 > -0.64
- Positive: Interest expense per share per price, % of 0.61 <= 0.75
- Negative: 42.26 < Shareholder equity ratio, % of 60.95 <= 63.63
Short-term TGTX quotes
Long-term TGTX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $233.66MM | $329.00MM | $616.29MM |
| Operating Expenses | $213.03MM | $287.07MM | $492.96MM |
| Operating Income | $20.63MM | $41.93MM | $123.32MM |
| Non-Operating Income | $-7.57MM | $-16.34MM | $-15.93MM |
| Interest Expense | $12.62MM | $24.03MM | $26.73MM |
| R&D Expense | $76.19MM | $94.29MM | $160.22MM |
| Income(Loss) | $13.06MM | $25.59MM | $107.39MM |
| Taxes | $0.39MM | $2.21MM | $-339.79MM |
| Net Income(Loss)* | $12.67MM | $23.38MM | $447.18MM |
| Stockholders Equity | $160.50MM | $222.36MM | $648.02MM |
| Inventory | $39.82MM | $110.46MM | $125.59MM |
| Assets | $329.59MM | $577.69MM | $1,063.25MM |
| Operating Cash Flow | $-31.41MM | $-40.52MM | $-24.77MM |
| Capital expenditure | $0.00MM | $0.04MM | $0.21MM |
| Investing Cash Flow | $-50.65MM | $-1.04MM | $13.80MM |
| Financing Cash Flow | $72.70MM | $128.53MM | $-89.73MM |
| Earnings Per Share** | $0.09 | $0.16 | $3.10 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.